2021 annual financial data
SAB Biotherapeutics, Inc. 2021 Operating margin
SAB Biotherapeutics, Inc. 2021 operating margin with verified reported values.
Direct answer
Operating margin was -22%.
Operating income was -13,393,000 USD and net income was -17,145,000 USD.
Operating cash flow was 1,986,873 USD.
Get free SAB Biotherapeutics, Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 60,876,000 USD
- Operating income
- -13,393,000 USD
- Net income
- -17,145,000 USD
- Operating cash flow
- 1,986,873 USD